Matrexa LLC was founded in Seattle, Washington in July of 2009 to develop extracellular matrix (ECM)-based products to help restore structural integrity and function to regenerating tissue. Research affiliations of Matrexa's founders have included the University of Washington, the Hope Heart Institute, the Benaroya Research Institute, Virginia Mason Medical Center, and the University of Auckland.
The extracellular matrix or ECM is a bioactive meshwork of proteins and carbohydrates in human and animal tissues in which cells exist and carry out the complex functions of life. The ECM and its molecules control the behavior and interactions between cells and impart biomechanical properties to living tissue. Our understanding of the role of the ECM is continuously evolving, and we are exploring its impact on human disease and tissue health and regeneration.
ECM Flourescent Micrographic Image
Molecules of the ECM, which include collagens, elastic fibers, proteoglycans, hyaluronan and glycoproteins, are necessary to maintain the health and integrity of human tissue. Insufficiencies and defects in the ECM and its molecules have been implicated in a host of human diseases and conditions, and also impact healing. We are working, not only to better understand the role of the ECM and its molecules, but to harness its power to treat human diseases, conditions, and to help regenerate healthy tissues in patients injured through disease and trauma. Matrexa's current efforts are focused on restoring elastic fibers to diseased and damaged tissues.
Matrexa Scientist Culturing Human Cells